Building a Resilient and Equitable Health System in South Africa

By Crystal Lubbe

November 7, 2024

resilient health system

The article titled “DTIC Calls for a Resilient Health System” on the SAnews website highlights the critical need for a resilient health system in South Africa, as emphasised by Deputy Minister of Trade, Industry and Competition, Zuko Godlimpi. He outlines several key points regarding the importance of establishing a robust health system capable of facing various challenges.

Call for a Resilient Health System

Deputy Minister Zuko Godlimpi has made it clear that building a resilient health system is a top priority. He highlighted that this system must be robust enough to withstand healthcare challenges that may arise in the future.

Equitable Access

Deputy Minister stressed the need for equitable access to healthcare. It is vital that all segments of the population have fair and equal opportunities to receive health services, minimizing disparities in healthcare access.

Priorities

The call for a robust healthcare framework includes focusing on several key areas:
Equitable Access: Ensuring that healthcare services are accessible to everyone, especially disadvantaged communities.
Human Resources: Enhancing the development of human resources within the healthcare sector to build a stronger workforce.
Infrastructure and Resources: Upgrading healthcare infrastructure and ensuring access to essential medicines, vaccines, and other health products.
Private Sector Engagement: Engaging the private sector to play an active role in strengthening the health system.

Broader Context

This initiative is part of a broader effort to improve the health system in South Africa. It aligns with the Presidential Health Compact, which aims to strengthen the overall health system, enhance access to healthcare, and prepare for the implementation of the National Health Insurance. Through these measures, the goal remains clear: to build a health system that serves all South Africans effectively.

Reference url

Recent Posts

FDA Approval Lumvoa Therapeutics
FDA Approval Lumvoa Therapeutics Redefines Treatment Landscape for Thyroid Eye Disease

By João L. Carapinha

June 29, 2026

The FDA Approval Lumvoa Therapeutics delivers the first full insulin-like growth factor-1 receptor (IGF-1R) antagonist for thyroid eye disease (TED), a rare autoimmune condition that triggers orbital inflammation, proptosis, diplopia, pain, and risk of vision loss.
HIV Treatment Access
Public-Private Partnership Enhances HIV Treatment Access Through Innovative Drug Integration

By João L. Carapinha

June 29, 2026

A new agreement between Merck and the ADAP Crisis Task Force significantly advances HIV Treatment Access by integrating the newly approved single-tablet regimen IDVYNSO™ (doravirine/islatravir) into state AIDS Drug Assistance Programs that served more than 250,000 people with HIV in 2024.
Cemiplimab Cervical Cancer Access
Cemiplimab Cervical Cancer Access Navigating Treatment and Value

By João L. Carapinha

June 24, 2026

Cemiplimab Cervical Cancer Access has been endorsed by NICE for adults with recurrent or metastatic cervical cancer that has progressed after platinum-based chemotherapy, provided patients have not previously received immunotherapy. The final draft guidance confirms that this PD-1 inhibitor deliv...